Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Alunbrig | Brigatinib | (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar and Mekinist | Dabrafenib and Trametinib | NSCLC BRAF V600 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ruzurgi | amifampridine | Lambert-Eaton myasthenic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo-Yervoy | nivolumab-ipilimumab | Malignant Pleural Mesothelioma (MPM) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Inqovi | Decitabine-Cedazuridine | Myelodysplastic Syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Enspryng | satralizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | ||
| Veltassa | patiromer | Hyperkalemia, adults (chronic kidney disease) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Inrebic | fedratinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jorveza | budesonide | Maintenance of Eosinophilic esophagitis in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 2, 2024